Clinical Researcher—August 2026 (Volume 40, Issue 4)
SITES & SPONSORS
Tyler Cobb
When a clinical trial site receives a Clinical Trial Agreement or Master Services Agreement from a sponsor, most of the negotiating energy goes to the budget, the payment schedule, and the operational terms. The insurance and indemnification sections tend to get a quick read and a signature. This article explains why those sections deserve more attention, walks through the provisions sites will most commonly encounter, and offers a set of practical questions site leaders can raise internally or with their legal counsel and insurance advisors before an agreement is executed.
The goal is not slowing down the contract process. In WCG’s 2025 Clinical Research Site Challenges Report, based on a survey of hundreds of research sites worldwide, 31% of sites named study start-up among their top challenges, with budgets and contracts cited among the largest drivers of those delays.{1} The goal is to make sure that the risk transfer terms a site accepts are terms its insurance program can actually support, because the gap between the two only becomes visible when a claim arrives.
Why the Insurance Section Matters
Insurance and indemnification provisions answer one question: who pays when something goes wrong. Under Good Clinical Practice standards, sponsors are generally expected to provide insurance or to indemnify the investigator and institution against claims arising from the trial, except for claims that arise from malpractice or negligence.{2} That exception is where site exposure lives. If a claim is framed as a deviation from the protocol, a coordinator error, or negligent conduct of the study, the sponsor’s indemnity may narrow or disappear, and the site is left looking to its own contractual protections and its own insurance policies.
Two features make these provisions easy to underestimate. First, the exposure is long tailed—indemnification obligations typically surface years after enrollment, once litigation develops, long after the study team that negotiated the agreement has moved on.{3} Second, the informed consent process does not shift this risk—U.S. Food and Drug Administration (FDA) regulations prohibit exculpatory language in consent documents through which a participant waives legal rights or releases the site from liability for negligence.{4} The contract and the insurance program are the mechanisms that actually allocate the money, which is exactly why they deserve a careful read.
Common Insurance Requirements in Sponsor Agreements
Most sponsor agreements contain an insurance schedule that requires the site to carry specified coverages at specified limits for the duration of the study, and often for a period of years afterward. Typical elements include:
- Liability limits—Requirements for commercial general liability and, where applicable, professional or medical liability coverage at stated per-occurrence and aggregate limits. Sites should confirm whether limits are required per study or shared across all activities, and whether policies written on a claims-made basis will need extended reporting coverage after the study ends.
- Additional insured status—A request that the sponsor be added to the site’s policies as an additional insured. Sites should understand whether their policies grant this by blanket endorsement when required by written contract or whether each sponsor must be scheduled individually, and whether the endorsement extends to completed operations rather than ongoing operations only.
- Certificates of insurance—A certificate of insurance (COI) is a summary document, not a policy. A COI that lists the sponsor tells the sponsor very little about whether the underlying endorsements actually match the contract. Sites should confirm that the endorsements behind the certificate say what the contract requires.
- Notice of cancellation and related conditions—Agreements often require advance written notice to the sponsor if coverage is cancelled or materially changed, along with conditions such as primary and non-contributory wording or a waiver of subrogation. Each of these is an endorsement-level item, and standard policies do not always include them automatically.
Indemnification: Understanding Who Pays When Something Goes Wrong
A typical structure is a two-way street. The sponsor indemnifies the site for claims arising from the protocol, the investigational product, or the sponsor’s use of study data. The site indemnifies the sponsor for claims arising from the site’s negligence, misconduct, or failure to follow the protocol. Carve-outs then reduce each party’s obligation to the extent the other party contributed to the loss.
The common misconception is treating a strong sponsor indemnity as a substitute for the site’s own coverage. It is not, for three reasons:
- The sponsor’s indemnity usually excludes exactly the allegations most likely to be aimed at the site, such as negligence and protocol deviation, and plaintiffs routinely plead those theories against every defendant.
- Indemnification is a promise to pay, not a payment. It generally requires litigation, tender, and often a dispute over whose conduct caused what before any money moves. In the meantime, the site funds its own defense unless a duty to defend is spelled out.
- Indemnity provisions frequently include strict notice requirements and control-of-defense conditions. A missed notice deadline can become an argument for reducing or denying the obligation, which is why sites benefit from language limiting that consequence to actual prejudice.
Sites should also distinguish indemnification from subject injury provisions. Indemnification responds to third-party claims and litigation. A subject injury clause is a separate, immediate commitment by the sponsor to pay for medical care when a participant is injured in the study, without any lawsuit. Sponsor templates do not always include one, and the two provisions are not interchangeable.
Coverage Gaps That Can Surface During a Claim
The recurring pattern in claims involving research sites is that the contract promised more than the insurance program delivered. What follows are some generic examples of how that happens:
- The site’s indemnity obligation extends to the sponsor’s affiliates, contract research organization, and agents, but the site’s liability policies respond only to the site’s own negligence, leaving a slice of the assumed obligation uninsured.
- The agreement requires additional insured status for completed operations, but the site’s endorsement covers ongoing operations only, so coverage for the sponsor evaporates once the study closes.
- The site carries a claims-made professional liability policy and later changes carriers without preserving the retroactive date or purchasing tail coverage, so a claim reported years after study completion falls outside both the old and new policies.
- An exclusion for clinical trials, investigational products, or contractual liability sits in a policy that was never reviewed against the research contract, and it is discovered at claim time.
None of these gaps is exotic. Each one is visible in advance if someone compares the contract language against the actual policy forms and endorsements rather than against the certificate.
Practical Questions Sites Should Ask Before Signing
Before executing a sponsor agreement, site leadership can work through a short list of questions with legal counsel and their insurance advisor:
- Does the indemnity we are giving match the indemnity we are receiving, and does our insurance program respond to the obligations we are assuming?
- Do our policy limits, additional insured endorsements, primary and non-contributory wording, and notice provisions actually satisfy the insurance schedule at the endorsement level rather than the certificate level?
- If our liability coverage is claims-made, what happens after this study ends? Who is responsible for maintaining coverage, for how long, and is that obligation written into the agreement?
- Does the agreement include a subject injury provision, and how is the payment amount for participant care defined?
- What are the notice deadlines for tendering an indemnity claim, and does the language limit the consequence of a missed deadline to actual prejudice?
Documentation habits matter as much as negotiation. Sites should keep executed agreements, insurance schedules, policies, and endorsements together; calendar the post-study coverage obligations; and revisit the file at every insurance renewal. When contract language is ambiguous, the time to request clarification or a revision is before signature, when the request costs a redline rather than a dispute.
Conclusion
Insurance and indemnification provisions decide who funds the worst day of a study, and they do so years before anyone knows whether that day will come. Sites that read the insurance schedule at the endorsement level, that treat sponsor indemnity as a complement to their own coverage rather than a substitute for it, that insist on clarity around subject injury and post-study obligations, and that ask their questions before signature will rarely be surprised at claim time. The review takes hours. The gaps it prevents can take years to litigate.
References
- WCG. 2025. Unveiling 2025’s Biggest Site Challenges: Data-Driven Insights to Optimize Site Success. ACRP Blog. https://acrpnet.org/2025/10/14/unveiling-2025s-biggest-site-challenges-data-driven-insights-to-optimize-site-success
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. 2025. ICH Harmonised Guideline: Good Clinical Practice (GCP) E6(R3), Section 3.14. https://database.ich.org/sites/default/files/ICH_E6(R3)_Step4_FinalGuideline_2025_0106.pdf
- King R. 2021. Risk Allocation for Clinical Trials: What You Need and Why. Clinical Researcher 35(1). https://acrpnet.org/2021/01/19/risk-allocation-for-clinical-trials-what-you-need-and-why
- U.S. Food and Drug Administration. Protection of Human Subjects: General Requirements for Informed Consent. 21 CFR Part 50.20 in the Code of Federal Regulations. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-50/subpart-B/section-50.20
Tyler Cobb (tcobb@towerstreetinsurance.com) is a Business Risk Advisor with Tower Street Insurance & Risk Management in Dallas, Texas, and blogger at https://lifesciencesliability.com/.
